2190 — Zylox-Tonbridge Medical Technology Co Cashflow Statement
0.000.00%
- HK$7.04bn
- HK$5.48bn
- CNY527.75m
- 52
- 10
- 68
- 36
Annual cashflow statement for Zylox-Tonbridge Medical Technology Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -66.6 | -100 | -200 | -114 | -78.7 |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | 5.74 | 22.4 | 55.9 | -5.84 | 16 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -1.75 | -13.9 | 14.2 | 1.8 | 125 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Payable / Accrued Expenses | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -53.1 | -82.3 | -116 | -91.3 | 98.4 |
Capital Expenditures | -41.6 | -45.1 | -89.6 | -145 | -191 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | -49 | -204 | -1,239 | 50.2 | -15.3 |
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -90.6 | -249 | -1,328 | -95 | -206 |
Financing Cash Flow Items | 179 | 336 | 399 | -0.722 | -1.25 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 179 | 346 | 2,810 | -30.3 | -11.5 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 35.6 | 13.4 | 1,359 | -213 | -119 |